T1	PROC 46 83	Evaluación de la eficacia y seguridad
T2	PROC 115 220	ENSAYO CLÍNICO MULTICÉNTRICO, PROSPECTIVO ALEATORIZADO, DOBLE CIEGO, PARALELO CONTROLADO FRENTE A PLACEBO
T3	PROC 629 665	consentimiento informado por escrito
#1	AnnotatorNotes T3	C0811741; Obtain informed written consent; Health Care Activity
T4	ANAT 282 293	MUCOSA ORAL
#2	AnnotatorNotes T4	C0026639; Oral mucous membrane structure; Body Part, Organ, or Organ Component
T5	DISO 336 357	INFECCIONES URINARIAS
#3	AnnotatorNotes T5	C0042029; Urinary tract infection; Disease or Syndrome
T6	PROC 380 433	EVALUACIÓN DE LA EFICACIA INMUNOMODULADORA, SEGURIDAD
T7	DISO 475 496	Infecciones urinarias
#4	AnnotatorNotes T7	C0042029; Urinary tract infection; Disease or Syndrome
T8	DISO 537 582	Infecciones de repetición del tracto urinario
T9	ANAT 567 582	tracto urinario
#5	AnnotatorNotes T9	C0042027; Urinary tract; Body Part, Organ, or Organ Component | C1280341; Entire urinary tract; Body System
T10	DISO 831 839	cistitis
#6	AnnotatorNotes T10	C0010692; Cystitis; Disease or Syndrome
T11	PROC 934 957	tratamientos supresivos
T12	PROC 962 972	profilaxis
#7	AnnotatorNotes T12	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T13	DISO 1170 1194	trastornos psiquiátricos
#8	AnnotatorNotes T13	C0004936; Mental disorders; Mental or Behavioral Dysfunction
T14	CHEM 87 92	MV140
#9	AnnotatorNotes T14	C3659064; uromune; Immunologic Factor · Pharmacologic Substance
T15	DISO 1261 1274	incontinencia
#10	AnnotatorNotes T15	C0021167; Incontinence; Disease or Syndrome | C0042024; Urinary Incontinence; Pathologic Function
T16	DISO 1303 1320	tumores genitales
T17	ANAT 1311 1320	genitales
#11	AnnotatorNotes T17	C0017420; Genitalia; Body Part, Organ, or Organ Component | C0227605; External genitalia; Body Part, Organ, or Organ Component | C0559522; Genital system; Body System
T18	DISO 1333 1358	tumores en vías urinarias
T19	ANAT 1344 1358	vías urinarias
#12	AnnotatorNotes T19	C0042027; Urinary tract; Body Part, Organ, or Organ Component | C1280341; Entire urinary tract; Body System
T20	DISO 1372 1380	litiasis
#13	AnnotatorNotes T20	C0023869; Lithiasis; Pathologic Function
T21	DISO 1394 1433	alteraciones en el sistema inmunológico
T22	ANAT 1413 1433	sistema inmunológico
#14	AnnotatorNotes T22	C0020962; Immune system; Body System | C1305754; Entire immune system; Body System
T23	CHEM 228 257	VACUNA BACTERIANA POLIVALENTE
T24	ANAT 348 357	URINARIAS
#15	AnnotatorNotes T24	C1508753; Urinary system; Body System
T25	ANAT 487 496	urinarias
#16	AnnotatorNotes T25	C1508753; Urinary system; Body System
T26	PROC 750 773	régimen de dosificación
T27	PROC 1034 1070	consentimiento informado por escrito
#17	AnnotatorNotes T27	C0811741; Obtain informed written consent; Health Care Activity
T28	PROC 901 929	medidas higiénico-sanitarias
T29	DISO 1215 1247	residuo postmiccional patológico
T30	Date 13 17	2013
T31	Route 263 277	VÍA SUBLINGUAL
T33	Duration 297 307	TRES MESES
T34	Duration 310 320	SEIS MESES
T35	LIVB 324 331	MUJERES
#18	AnnotatorNotes T35	C0043210; Woman; Population Group
T37	LIVB 669 676	Mujeres
#19	AnnotatorNotes T37	C0043210; Woman; Population Group
T38	Age 696 714	entre 18 y 75 años
T39	LIVB 777 784	Sujetos
#20	AnnotatorNotes T39	C0681850; Study Subject; Group
T40	Duration 843 863	los últimos 12 meses
T41	LIVB 867 874	Sujetos
#21	AnnotatorNotes T41	C0681850; Study Subject; Group
T44	Neg_cue 1013 1015	No
T48	LIVB 235 245	BACTERIANA
#22	AnnotatorNotes T48	C0004611; Bacteria; Bacterium
T32	Time 973 983	postcoital
T36	Time 1223 1236	postmiccional
A1	Assertion T27 Negated
A2	Status T10 History_of
A3	Status T28 History_of
A4	Status T11 History_of
A5	Status T12 History_of
#23	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity
#24	AnnotatorNotes T23	C3659064; uromune; Immunologic Factor · Pharmacologic Substance
#25	AnnotatorNotes T31	C2316433; Administration of substance via sublingual route; Therapeutic or Preventive Procedure 
#26	AnnotatorNotes T2	C1096776; Multicenter Study; Research Activity + C0033522; Prospective Studies; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product 
#27	AnnotatorNotes T6	C1963758; Immunomodulation; Therapeutic or Preventive Procedure + C0511730; Identify product efficacy and safety issues; Health Care Activity
#28	AnnotatorNotes T8	C0262655; Recurrent urinary tract infection; Disease or Syndrome 
#29	AnnotatorNotes T11	C0563648; Suppression treatment; Therapeutic or Preventive Procedure 
#30	AnnotatorNotes T18	C0042076; Urologic Neoplasms; Neoplastic Process 
#31	AnnotatorNotes T21	C4021753; Abnormality of the immune system; Pathologic Function (?)
T42	Neg_cue 879 881	no
T43	Observation 888 898	respondido
A6	Assertion T43 Negated
#32	AnnotatorNotes T43	C4055223; Clinical Response; Finding
R1	Negation Arg1:T42 Arg2:T43	
R2	Overlap Arg1:T43 Arg2:T28	
R3	Overlap Arg1:T43 Arg2:T11	
R4	Overlap Arg1:T43 Arg2:T12	
R5	Overlap Arg1:T12 Arg2:T32	
T45	CONC 1100 1113	rango de edad
A7	Assertion T45 Negated
#33	AnnotatorNotes T45	C5418925; Study Age Range; Quantitative Concept
T46	Neg_cue 1079 1081	no
R6	Negation Arg1:T46 Arg2:T45	
T47	Neg_cue 1129 1131	No
T49	Observation 1147 1158	cooperación
A8	Assertion T49 Negated
#34	AnnotatorNotes T49	C1998024; Cooperative mental state; Finding (?)
R7	Negation Arg1:T47 Arg2:T49	
R8	Location_of Arg1:T25 Arg2:T7	
R9	Location_of Arg1:T9 Arg2:T8	
R10	Location_of Arg1:T24 Arg2:T5	
T50	Quantifier_or_Qualifier 808 827	mínimo, 3 episodios
R11	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T50	
R12	Overlap Arg1:T10 Arg2:T40	
R13	Experiences Arg1:T39 Arg2:T10	
R14	Experiences Arg1:T41 Arg2:T43	
R15	Experiences Arg1:T41 Arg2:T11	
R16	Experiences Arg1:T41 Arg2:T28	
R17	Experiences Arg1:T41 Arg2:T12	
R18	Negation Arg1:T44 Arg2:T27	
T51	Quantifier_or_Qualifier 1195 1201	graves
#35	AnnotatorNotes T51	C1547227; Severe -Severity of Illness Code; Intellectual Product
R19	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T51	
R20	Overlap Arg1:T49 Arg2:T13	
R21	Overlap Arg1:T29 Arg2:T36	
T52	Quantifier_or_Qualifier 1275 1289	moderada-grave
#36	AnnotatorNotes T52	C1299393; Moderate to severe; Qualitative Concept
R22	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T52	
R23	Location_of Arg1:T17 Arg2:T16	
#37	AnnotatorNotes T16	C0679347; Genital neoplasm; Neoplastic Process | C2314937; Malignant neoplasm of genital structure; Neoplastic Process
R24	Location_of Arg1:T19 Arg2:T18	
R25	Location_of Arg1:T22 Arg2:T21	
R26	Has_Route_or_Mode Arg1:T23 Arg2:T31	
R27	Location_of Arg1:T4 Arg2:T23	
R28	Before Arg1:T23 Arg2:T33	
R29	Before Arg1:T23 Arg2:T34	
R30	Experiences Arg1:T35 Arg2:T23	
R31	Experiences Arg1:T35 Arg2:T5	
T53	Quantifier_or_Qualifier 358 371	DE REPETICIÓN
#38	AnnotatorNotes T53	C2945760; Recurrent; Temporal Concept
R32	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T53	
T54	Observation 436 451	IMPACTO CLÍNICO
#39	AnnotatorNotes T54	C0235735; Unexpected therapeutic effect; Finding (?)
R33	Experiences Arg1:T35 Arg2:T54	
R34	Causes Arg1:T23 Arg2:T54	
T55	Quantifier_or_Qualifier 497 510	de repetición
#40	AnnotatorNotes T55	C2945760; Recurrent; Temporal Concept
R35	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T55	
T56	Observation 728 773	capaces de cumplir el régimen de dosificación
#41	AnnotatorNotes T56	C2364172; Adherence To Medication Regime; Finding (?)
R36	Overlap Arg1:T56 Arg2:T26	
#42	AnnotatorNotes T32	C1439871; post coitus; Temporal Concept
#43	AnnotatorNotes T26	C4684645; Dosage Regimen; Therapeutic or Preventive Procedure
A9	Experiencer T35 Patient
A10	Experiencer T37 Patient
A11	Experiencer T39 Patient
A12	Experiencer T41 Patient
